Implementing molecular methods may involve purchasing an equipment platform representing a significant capital investment. Assay reagents are frequently more expensive on a cost-per-test basis than either culture or antigen detection methods. Reimbursement issues, although improving, can be more complex. Realistically, implementations of molecular methods are likely to represent increased costs that need to be weighed against the potential benefits that can be realized.
When considering the implementation of a molecular method, the following question should be asked:
Will the methods significantly impact/improve clinical management and patient outcomes, reduce antimicrobial costs and lengths of stay, and/or facilitate infection control, epidemiology, or antibiotic stewardship programs?
The answer may not be "yes" for every infectious disease agent for which molecular methods are now available.
